Fennec Pharmaceuticals delivered its strongest commercial quarter yet, and the most important development was not the top line but how much of it reached the bottom line. Third-quarter earnings of $0.12 per share beat the $0.09 consensus by 33.3%, compared with a $0.02 loss a year ago. Earnings Whispers measures that as 700.0% earnings growth. Revenue of $19.61 million topped the $18.91 million consensus by 3.7% and grew 57.3% year over year. The central tension is that profitability is inflecting sharply while the revenue growth rate is clearly moderating. Investors now have to decide whether operating leverage and improving demand indicators can outrun tougher comparisons.

The quality of the beat mostly holds up, though it deserves some parsing. Net product sales of $19.4 million rose 56%. Total revenue also includes $183,000 of non-cash amortization tied to the Norgine license, which management excludes from adjusted EBITDA. Adjusted EBITDA climbed to $5.8 million from $2.8 million in the second quarter, lifting the margin from 16% to 30%. EBITDA rose about $3 million on roughly $2.3 million of added revenue.

Some of that leverage came from cost relief rather than pure scale:

• **General and administrative expense:** fell to $3.9 million from $5.4 million a year earlier as litigation activity concluded.
• **Stock compensation:** declined to $1.4 million from $2.2 million.
• **Interest expense:** effectively disappeared, leaving no debt on the balance sheet.
• **Selling and marketing:** went the other way, rising to $10.1 million from $6.5 million to fund the expanded sales force.

GAAP results still swung decisively. Operating income was $4.7 million versus a small loss a year ago, and net income was $4.6 million. Cash generation was the cleanest proof point. Operating cash flow was a record $6.7 million, and cash rose to $48.7 million from $41.2 million. That outcome contradicts the expectation management set on the second-quarter call that cash would decline.

The call tells a story of a sales expansion starting to pay off. Sequential sales growth held at roughly 13.5%, consistent with the second quarter, extending revenue gains to eight straight quarters. Program enrollments rose 23% sequentially and completed infusions jumped 58%. Management cited a record carryover of patients, planned infusions and vials into the fourth quarter, along with a strong October. The tone shifted noticeably. Earlier in the year management was asking investors to give the expanded field force time; now it pointed to visible results and strong fourth-quarter visibility.

New commercial levers also surfaced:

• a formulary win at a large Midwestern academic center and its home infusion service, with meaningful uptake already in October and November;
• a GPO data partnership feeding an internal alert program that targets adolescent and young adult (AYA) cisplatin prescribers.

Still, the gap between 58% infusion growth and 13% revenue growth is worth watching. Management attributed the difference to timing, patient mix and adherence, so converting that demand into sales is not guaranteed.

Bears have legitimate ammunition:

• **Slowing growth:** year-over-year growth slowed to about 56% from roughly 78% in the second quarter and 73% in the first.
• **Rising spend:** full-year cash operating expense is now framed as "low 50s" millions, versus roughly $50 million in prior calls, though management expects the fourth quarter to be the lowest-spend quarter of the year.
• **No guidance:** there is still no formal revenue or EBITDA guidance, and the 2027 guidance idea floated last quarter received no update.
• **Partnering and international:** a Japan licensing partner remains unsigned despite repeated "stay tuned" commentary, and Norgine's ex-U.S. progress went unaddressed.
• **Concentration:** testicular cancer represents a little over half the business.

On the catalyst side, the Japanese STS-J01 data presented orally at SIOP showed significant hearing protection. Interim City of Hope data in adult metastatic testicular germ cell tumors, due in early January, could matter for the core patient segment, since current labeling covers localized, non-metastatic pediatric disease.

The market had not been rewarding the story heading into the report. Shares closed at $10.64 on the day before the release, 12.5% below the $12.16 opening price after the August report. The stock printed a 52-week high of $13.25 on that August reaction day, then slid to a $9.20 low on November 6. It rebounded 15.7% off that low into the print but still sat 19.7% below the August peak. It remains 14.3% above its 200-day moving average, so the longer-term trend is intact even after the post-August fade. Investor sentiment improved from -0.14 to +0.02, a meaningful move from mildly negative to roughly neutral, but hardly euphoric. The Earnings Whispers trend readings are mixed: sequential-growth and momentum signals are positive, while AVWAP remains negative, consistent with a stock still working off its post-August fade.

The bottom line is that Fennec showed this quarter it can turn PEDMARK demand into real earnings and cash, with a 30% adjusted EBITDA margin, a debt-free balance sheet and accelerating patient activity entering the fourth quarter. The counterweights are decelerating year-over-year growth, creeping operating spend, heavy reliance on testicular cancer and continued silence on guidance and partnerships. Investors are not paying up for the growth story, given a share price still well off its August high and only neutral sentiment. That leaves room for the upside if record carryover converts into fourth-quarter revenue, but it also means management will need formal guidance or a partnership to fully reset the narrative.